

Relationship between smoking and metabolic syndrome

Hellas Cena, Maria Luisa Fonte, and Giovanna Turconi

Obesity and smoking are important causes of morbidity and mortality worldwide. The diseases and conditions associated with smoking make tobacco use one of the leading causes of death worldwide. In the World Health Organization European region, overweight and obesity are responsible for many chronic diseases, causing more than one million deaths each year. Smoking cessation is associated with a significantly reduced mortality risk in every body-mass-index group. Reductions in smoking and obesity would increase both the psychophysical well-being of the population and its economic productivity; it would also reduce the direct costs of pharmacological therapies and other forms of treatment. The aim of this review is to critically evaluate how tobacco smoking and obesity interact to reduce life expectancy, and to offer a comprehensive view of this issue that should be useful for clinical practice.

© 2011 International Life Sciences Institute

INTRODUCTION

Obesity, with its comorbidities, and smoking are important causes of morbidity and mortality worldwide.^{1,2} The diseases and conditions associated with smoking make tobacco use one of the leading causes of death in the world,³ accounting for about five million deaths annually, which is equivalent to 1 in 10 adults globally.

According to the Framingham study, obese individuals who smoke have a 14-year reduction in life expectancy at the age of 40 years.⁴ A large prospective study showed that smoking coupled with obesity contributes substantially to all-cause mortality, with a 3.5–5-fold greater risk for severely obese current smokers than for normal-weight nonsmokers.⁵

It is clear that smoking and obesity are the main causes of preventable morbidity and mortality in developed countries.⁶ In the context of the current worldwide obesity epidemic, and with the high prevalence of smoking, it is very important to understand the relationship between smoking and obesity.

The aim of this review is to offer a comprehensive view of the interaction between tobacco smoking and

obesity and to underline how this interaction, far from being an efficient way to control body weight, leads to a global reduction in life expectancy.

DEFINITION OF METABOLIC SYNDROME

The metabolic syndrome (MBS) is a disease of adulthood, recently classified nosologically and subject to etiopathogenetic and epidemiological redefinitions.⁷ Currently, MBS is a widely accepted concept applied to centrally obese patients with an increased risk of cardiovascular disease and diabetes.⁸ From a physiopathological perspective, this syndrome is associated with multiple metabolic changes and hemodynamic disorders, such as reduced glucose tolerance, type 2 diabetes, insulin resistance, arterial hypertension, altered lipid metabolism (hypertriglyceridemia, hypercholesterolemia, reduced high-density lipoprotein, and elevated low-density lipoprotein), and abnormalities of the coagulation system. In these patients, there is a very high risk of complications, especially vascular ones, such as atherosclerotic disease, acute myocardial infarction, and stroke.^{9,10}

Affiliations: *H Cena, ML Fonte, and G Turconi* are with the Department of Applied Health Sciences, Section of Human Nutrition and Dietetics, Faculty of Medicine, University of Pavia, Pavia, Italy

Correspondence: *H Cena*, Department of Applied Health Sciences, Section of Human Nutrition and Dietetics, Faculty of Medicine, University of Pavia, Via Bassi 21, Pavia 27100, Italy. E-mail: hcena@unipv.it, Phone: +39-0382-987542, Fax: +39-0382-987570.

Key words: *body composition, health, inflammation, obesity, smoking*

doi:10.1111/j.1753-4887.2011.00446.x

Nutrition Reviews® Vol. 69(12):745–753

Although the clinical importance of this syndrome is recognized today, many uncertainties remain and a lively debate on its diagnostic criteria is ongoing. Although MBS was identified 40 years ago, the actual criteria that define this syndrome have been formulated very recently. There are currently five definitions of MBS, issued by five different scientific associations: the World Health Organization (WHO),¹¹ the National Cholesterol Education Program–Adult Treatment Panel III (NCEP–ATP III),¹² the American Association of Clinical Endocrinologists,¹³ the European Group for the Study of Insulin Resistance,¹⁴ and the International Diabetes Federation.¹⁵

It is important to emphasize that when any definition is considered, each diagnostic criterion is in itself an independent risk factor for cardiovascular events, and increases the risk of such events by 30%.¹⁶

There is a high prevalence of MBS in the general population, varying from 17.8% to 34.1%, depending on whether the WHO or NCEP–ATP III diagnostic criteria are used, respectively. The maximum peak age is between 65 and 74 years.¹⁷ With the increased incidence of obesity in young populations, these data may well change over the next few years. We should bear in mind that all ethnic groups are affected and that the risk of cardiovascular events is almost double the risk in unaffected subjects. A study published by the *Journal of the American Medical Association* in 2002¹⁸ reported a prevalence of MBS of greater than 40% in the US population. In Europe, low-prevalence areas (17% in men and 8% in women in Finland) contrast sharply with regions where its prevalence is high, such as the Mediterranean.¹⁹ In Italy, for example, MBS affects 23% of men and 21% of women. The prevalence of MBS among menopausal women is particularly significant, reaching up to 32%.¹⁷ It is also important to note that 5% of adolescents are affected by MBS.²⁰

ASSOCIATION BETWEEN TOBACCO SMOKING AND METABOLIC SYNDROME

Smoking is widely accepted as a major risk factor for cardiovascular disease.²¹ Previous studies have shown that smoking reduces insulin sensitivity, induces insulin resistance,^{21–26} and enhances cardiovascular risk factors, such as elevated plasma triglycerides,^{27–30} reduced high-density lipoprotein–cholesterol,^{27–31} and hyperglycemia.²² Several studies have also shown that smoking is associated with metabolic abnormalities and increases the risk of MBS.^{32–34}

Nakanishi et al.³² reported that subjects who habitually smoked tobacco had a 1.07–1.66-fold greater risk of developing MBS than subjects who did not smoke. Weitzman et al.²⁰ have demonstrated for the first time a dose-responsive, cotinine-confirmed relationship between

tobacco smoke and the severity of MBS. Weitzman's study also demonstrated an association between tobacco smoke and MBS in adolescents. The authors reported that exposure to tobacco smoke, whether through active or passive smoking, is associated with a fourfold increase in the risk of the MBS among adolescents who are overweight or at risk of overweight.

Saarni et al.³⁵ investigated the association between adolescent smoking and overweight or abdominal obesity in adulthood. They reported that smoking is a risk factor for abdominal obesity in both sexes and for overweight in women.

In Kawada's 1-year follow-up study,³⁶ current smokers had a higher risk of MBS than nonsmokers, independent of age, body mass index (BMI), insulin resistance, uric acid, and other lifestyle factors. In contrast, ex-smokers did not have a significantly greater risk of MBS than nonsmokers.

The most effective way for smokers to reduce their risk of MBS and cardiovascular disease is to stop smoking.³⁷ However, Nakanishi et al.³² highlighted that smoking cessation is also associated with a 1.3-fold risk of MBS as a result of subsequent body weight gain.

INSULIN RESISTANCE

The main clinical component of MBS is insulin resistance. MBS and glucose intolerance are regarded as disturbances with a common background and strong interrelationship.³⁸ Cigarette smoking may directly reduce insulin sensitivity by increasing circulating levels of insulin-antagonistic hormones (i.e., catecholamines, cortisol, and growth hormone) and increasing lipolysis, resulting in high circulating levels of free fatty acids.³² Nicotine, carbon monoxide, and other metabolites derived from smoking also play important roles in insulin resistance. Furthermore, several mechanisms by which cigarette smoking promotes dyslipidemia have been proposed, including reduced lipoprotein lipase activity, increased 3-hydroxy-3-methylglutaryl-CoA reductase activity, increased glucose-6-phosphatase dehydrogenase activity, and increased central obesity.²⁷ Other studies may have lent some insight into this process, in that recent work has indicated that epigenetic mechanisms may be involved in MBS and type 2 diabetes.^{39–41}

There is important evidence that variation in DNA methylation patterns is linked to various pathological conditions, including insulin resistance,³⁹ and that it may be responsible for MBS onset, beginning from developmental programming in the prenatal period.³⁹ It has been demonstrated⁴² that smoking is related to aberrant DNA methylation patterns and that one of the mechanisms by which tobacco smoke promotes lung cancer is the inactivation of key genes through pro-

moter hypermethylation.⁴³ The literature suggests that a plausible underlying biological mechanism is required to explain the impact of tobacco smoke on MBS pathogenesis.

The insulin response to oral glucose loading is more pronounced in smokers than in nonsmokers,²² and insulin resistance is dose-dependently related to smoking.⁴⁴ In healthy men, chronic smoking is associated with high plasma insulin concentrations, regardless of other factors known to influence insulin sensitivity.⁴⁵ The long-term use of nicotine gum is also associated with hyperinsulinemia and insulin resistance.⁴⁶ In nonobese men, insulin sensitivity improved 8 weeks after smoking cessation, despite a body weight increase.⁴⁷ The risk of type 2 diabetes is also greater in smokers than in nonsmokers.^{48,49}

In the Physicians' Health Study, a 70% greater risk of diabetes was reported in men who smoked more than 20 cigarettes a day than in nonsmokers.⁵⁰ Similar observations were made for women.^{51–53} The risk of diabetes in former smokers decreases progressively as the length of time since smoking cessation increases,^{53,54} and it returns to normal after a few years.⁵³ Smoking appears to aggravate insulin resistance in individuals with type 2 diabetes⁵⁵ and impairs glycemic control.⁴⁸

Overall, despite some conflicting observations, the evidence indicates that smoking leads to visceral fat accumulation and insulin resistance, and it increases the risk of MBS and type 2 diabetes.

CENTRAL OBESITY

Insulin resistance is the primary consequence of localized visceral fat. There are two mechanisms responsible for a reduction in insulin sensitivity in the peripheral tissues⁵⁶: 1) excessive accumulation of fat, with the development of an inflammatory state, increased production of proinflammatory cytokines⁵⁷ by adipocytes, and infiltration of macrophages into the adipose tissue; 2) metabolic variations in the same adipocytes, which reduce their capacity to store fats that consequently migrate to other nonadipose organs, such as the liver, heart, muscle, and pancreas, causing a toxic response known as "lipotoxicity."⁵⁸

Mizuno et al.⁵⁹ reported that waist circumference is significantly higher in obese subjects who smoke than in those who do not. Smoking seems to accelerate visceral fat accumulation and promote obesity-related disorders. Waist circumference is strongly associated with visceral fat mass,⁶⁰ which is influenced by the plasma cortisol concentration.⁶¹ Smokers have higher fasting plasma cortisol concentrations than nonsmokers.^{62,63} Higher cortisol concentrations may be a consequence of the stimulation of sympathetic nervous system activity, which is induced by smoking.^{64,65}

Sex hormones may also be involved.⁶⁶ Women's visceral fat mass increases when their estrogen concentrations decrease and their testosterone concentrations increase, typically after menopause.⁶⁶ In other situations, lack of estrogens and excess androgens have been associated with visceral adipose tissue accumulation in women,^{67,68} as is also reported after the administration of testosterone.⁶⁹ Female smokers show no change in their absolute estrogen concentrations, but they have higher androgen concentrations^{63,70} and lower bioavailable estrogens⁷¹ than do female nonsmokers. Testosterone concentrations may also be affected by smoking, although the data are inconsistent.^{72,73}

In men, visceral fat increases when testosterone concentrations decrease,⁷⁴ and the administration of testosterone to middle-aged men reduces their visceral adipose tissue by increasing lipolysis.⁷⁵ Smoking may reduce testosterone concentrations in men.⁷⁶ Overall, these results suggest that, in addition to excess cortisol, an imbalance between male and female sex hormones in women and a reduction of testosterone in men may be involved in the effect of smoking on visceral adipose tissue.

TOBACCO USE AND OREXIGENIC HORMONES

Leptin has received attention for its possible association with body weight and tobacco use. The presence of insulin resistance in long-term nicotine gum chewers⁷⁷ suggests that nicotine is the major constituent of tobacco responsible for these metabolic aberrations. Leptin levels are higher in women,^{78,79} and they are directly related to a larger fat mass.⁸⁰ It has recently been speculated that leptin also has metabolic effects and that resistance to the effects of leptin constitutes a link between obesity and insulin resistance.⁸¹

Leptin is a peptide hormone released by adipose tissue that signals the extent of fat storage. It binds to hypothalamic receptors, modulating the release of neuropeptides with anorexigenic and orexigenic effects.^{82,83} Individuals with similar adiposity patterns show remarkable differences in their serum leptin levels,⁸⁴ indicating that this sequence of events is neither linear nor similar in all individuals. The relationship between leptin and adiposity is even more complex if more than one factor, such as tobacco use, is involved.

Smokers should be expected to eat less and show higher energy expenditure because of the high levels of circulating leptin induced by inhaled nicotine. It would be reasonable to infer that high serum levels of leptin are responsible for the lower BMIs seen in smokers, because leptin, when bound to its hypothalamic receptors, promotes the release of anorexigenic neurotransmitters, leading to a reduction in body weight.⁸² The chronic use

of tobacco may elevate serum levels of leptin, increasing the expression of leptin or reducing its renal depuration. Also, leptinemia may be influenced by nicotine through induction of corticosteroid release.⁸³

Many studies^{77,82,83} have generated results that support the hypothesis that the higher levels of leptin in smokers originate from a resistance mechanism that leads to lower hormone sensitivity. However, there are conflicting results in the literature about the serum levels of leptin in smokers.^{83–85} Some studies^{86,87} have found that leptin levels are significantly lower in smokers than in nonsmokers after adjustments are made for BMI, sex, and age. Other studies^{88,89} suggest that leptin levels are not associated with smoking. Several investigations have shown, however, that long-term use of nicotine is associated with elevated circulating leptin levels. These results support the view that leptin is directly or indirectly related to insulin sensitivity in men.

Leptin levels have also been evaluated after smoking cessation, with equally contradictory findings. A significant increase in postcessation serum leptin levels, rather than the expected reduction, has been demonstrated in some studies.^{83,90} It is important to emphasize that the discrepancies among studies can be explained by differences in such factors as ethnic groups, age, and health status of the participants.⁹⁰ Another possible explanation is that nicotine could indirectly modify leptin levels, thereby maintaining a low BMI and increasing leptin sensitivity.⁹⁰

Conflicting findings regarding the relationship between leptinemia and smoking status can also be explained by a difference in the hormone receptors. Genetic variations in the leptin receptor have been correlated to overweight and obesity,^{91–94} while an association with smoking cessation has not yet been confirmed. Martin et al.⁸⁴ reported that the effects of smoking are linked to certain specific genotypes and circulating leptin, suggesting that genetic inheritance could partly explain different leptin concentrations in smokers, nonsmokers, and individuals in course of cessation. Leptin levels may be affected by sex, menopause, phase of the hormonal cycle, and by central or peripheral fat deposit.⁹⁵

Discrepancies have also been reported regarding the levels of other peptides that regulate food intake, such as neuropeptide Y,⁹⁶ orexins,⁹⁷ and ghrelin.⁹⁰ The administration of inhaled nicotine markedly reduced the food intake of rats by inhibiting the synthesis of neuropeptide Y, one of the orexigenic hormones.^{98,99} Therefore, smokers may eat less because of increased leptin activity (or leptin receptors activity) with subsequent reduced liberation of neuropeptide Y. During smoking cessation, the lack of nicotine may reduce leptinemia, thus decreasing leptin inhibitory effects on neuropeptide Y, and, finally, increase

appetite.¹⁰⁰ Ghrelin is another hormone involved in the regulation of satiety and hunger. It induces appetite in an action mediated by neuropeptide Y. Some studies reported that serum levels of ghrelin are associated with smoking status, but not to the number of cigarettes consumed per day.¹⁰¹

Contrary to expectations, Lee et al.⁹⁰ reported that after smoking cessation, the concentration of leptin in serum increases, whereas that of ghrelin decreases. These findings demonstrate that the changes in the leptin–ghrelin–neuropeptide Y system might be the consequence, rather than the cause, of the changes in body weight observed after smoking cessation, probably correlated with the lack of nicotine's direct effects on the central nervous system.⁹⁰

SMOKING CESSATION AND WEIGHT GAIN

Cigarette smoking is a leading preventable cause of death and disability, but weight gain after quitting smoking^{64,85,102} is commonly cited as a primary reason for not trying to quit or for relapsing after cessation. Women seem to be somewhat more susceptible to weight gain following smoking cessation than men. In a 10-year study, the mean weight gain attributable to smoking cessation was 5.0 kg in women and 4.4 kg in men.¹⁰³ Multiple studies have shown that 33–75% of ex-smokers report weight gain within the first year of cessation.¹⁰⁴

Numerous cross-sectional studies have indicated that BMI is lower in cigarette smokers than in nonsmokers,^{101,102,105} and that leanness correlates directly with the duration but not the intensity of smoking. Generally, the literature reports an association between a longer duration of smoking and a lower BMI.^{103,106,107}

Recent statistical analyses of datasets from both the 2005–2006 National Health and Nutrition Examination Survey¹⁰⁵ and the 2005 National Health Interview Survey¹⁰⁸ confirm the findings of previous studies that smokers weigh significantly less than nonsmokers. However, Kim et al.¹⁰⁹ reported that continuous smokers show a greater weight gain than nonsmokers and they speculated that continuous smokers are less physically active. Another recent study¹¹⁰ reported no significant differences in the mean BMIs of smokers and nonsmokers among either males or females.

The exact cause of weight gain after smoking cessation is unclear. Two main hypotheses are reported in the literature. The first is that smoking increases energy expenditure because nicotine increases the metabolic rate, so energy expenditure is reduced with cessation.^{104,111,112} In 1986, Hofstetter et al.¹¹³ reported that the 24 h energy expenditure by smokers is increased by 140–200 kcal/day on a day with smoking relative to that

on a day without smoking, with no corresponding change in the mean basal metabolic rate. Further studies have since yielded conflicting results, predominantly finding an increase in the resting metabolic rate (RMR) shortly after nicotine administration. Walker et al.¹¹⁴ found a 6% increase in RMR after 20 min of smoking and Dallosso et al.¹¹² reported a 3% increase in RMR after smoking a single cigarette. However, several studies have failed to find a corresponding increase in RMR, when measured before and after smoking a single cigarette.^{115,116} Bradley et al.¹¹⁰ measured energy expenditure with doubly labeled water in a group of current smokers during a 2-week period in which the subjects lived at home and undertook their normal activities, and reported that the total energy expenditure of the male and female smokers did not differ significantly from that of nonsmokers. Although the total number of current smokers was small (only 47 individuals), the evidence reported in that study indicates that weight gain following smoking cessation is the result of increased caloric consumption and reduced total energy expenditure. The second hypothesis explaining the weight gain observed after tobacco cessation is that smoking alters energy intake by inducing an anorexic effect,¹¹¹ and by extension, smoking cessation leads to weight gain because of increased appetite and intake.¹¹⁷

CONCLUSION

An important consequence of smoking is a hormonal imbalance that is conducive first to an accumulation of central fat, and then to insulin resistance. The latter condition may represent a major link between cigarette smoking and the risk of cardiovascular disease.³⁷

Current smokers have the highest mortality rates across all BMI and waist circumference groups,¹¹⁸ and smoking cessation is associated with a significantly lower mortality risk in every BMI and waist circumference group. The longer someone is a former smoker, the lower their mortality risk.¹¹⁹ Although losing weight may reduce the mortality risk in current smokers, smoking cessation is related to a stronger reduction in risk.

It is well known that smoking cessation is associated with weight gain⁶⁴ and an increase in waist circumference,¹²⁰ possibly because of a reduced metabolic rate and increased caloric intake.¹¹⁷ However, weight gain is not likely to counteract the health benefits of smoking cessation. A recent study based on data from the National Health and Nutrition Examination Survey showed that a substantial reduction in smoking prevalence has only a small effect on increasing the prevalence of obesity and reducing the prevalence of healthy weight.¹⁰² Moreover, smoking cessation has the great benefit of reducing the risk of MBS, especially in subjects with fatty liver.¹²¹

These findings indicate that greater emphasis should be placed on the risk of central obesity, insulin resistance, and associated conditions among smokers, in particular, although concerns about post-cessation weight gain may deter many individuals from quitting smoking. Smokers should be made aware that smoking is not an efficient way to control body weight, does not help prevent obesity, and could favor visceral fat accumulation and increase the risk of MBS and diabetes. It is, indeed, clear that visceral obesity is a factor that should itself be considered a type of pathology, and which must be tackled as early as possible.

This is a perspective of great interest to all parties involved in primary and secondary prevention. To emphasize the importance of an early approach to this problem, it is important to remember the extent of the obesity problem. It is estimated that in the WHO European region, overweight and obesity are responsible for approximately 80% of type 2 diabetes, 35% of ischemic heart disease, and 55% of hypertension cases in adults, causing more than one million deaths each year and 12 million life-years spent in poor health.¹²²

It is also estimated that obesity is responsible for approximately 6% of national healthcare assistance costs.¹²³ Therefore, a reduction in smoking and smoking-related obesity will increase the psychophysical well-being of the population and its economic productivity. This would be accompanied by a reduction in pharmacological therapies and other forms of treatment, resulting in a considerable reduction in direct costs.

Acknowledgment

Declaration of interest. The authors have no relevant interests to declare.

REFERENCES

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA*. 2004;291:1238–1245.
2. Haslam DW, James WP. Obesity. *Lancet*. 2005;366:1197–1209.
3. World Health Organization. *Tobacco Free Initiative: Why Is Tobacco a Public Health Priority*. 2011. Available at: http://www.who.int/tobacco/health_priority/en/. Accessed 31 January 2011.
4. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. *Ann Intern Med*. 2003;138:24–32.
5. Freedman DM, Sigurdson AJ, Rajaraman P, et al. The mortality risk of smoking and obesity combined. *Am J Prev Med*. 2006;1:355–362.
6. Ezzati M, Lopez AD. Regional, disease specific patterns of smoking attributable mortality in 2000. *Tob Control*. 2004;13:388–395.

7. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2005;28:2289–2304.
8. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet*. 2010;375:181–183.
9. Sattar N. Why metabolic syndrome criteria have not made prime time: a view from the clinic. *Int J Obes*. 2008;32(Suppl):S30–S34.
10. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. *Arch Intern Med*. 2005;165:2644–2650.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of WHO consultation. *Diabetes Med*. 1998;15:539–553.
12. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. *Circulation*. 2002;106:3143–3421.
13. Einhorn D, Reaven D, Reaven GM, et al. American College of Endocrinology position statement on the insulin resistance syndrome. *Endocr Pract*. 2003;9:240–252.
14. Balkau B, Charles MA, for the European Group for the Study of Insulin Resistance. Comment to the provisional report from the WHO consultation. *Diabetic Med*. 1999;16:442–443.
15. Alberti G, Zimmet PZ, Shaw J, Grundy SM. *International Diabetes Federation 2006: The IDF Consensus Worldwide Definition of the Metabolic Syndrome*. 2006. Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed 11 February 2011.
16. Koskinen J, Kahonen M, Viikari JS, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima media thickness progression in young adults: the Cardiovascular Risk in Young Finns study. *Circulation*. 2009;120:229–236.
17. Istituto Superiore di Sanità. *Progetto Cuore*. 2009. <http://www.cuore.iss.it/eng/prevention/prevention.asp>. Accessed 31 October 2011.
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002;287:356–359.
19. Vanhala MJ, Kumpusalo EA, Pitkälä TK, Takala JK. Metabolic syndrome in a middle-aged Finnish population. *J Cardiovasc Risk*. 1997;4:291–295.
20. Weitzman M, Cook S, Auinger P, et al. Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. *Circulation*. 2005;112:862–869.
21. Frati AC, Iniestra F, Ariza CR. Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors. *Diabetes Care*. 1996;19:112–118.
22. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. *Lancet*. 1992;339:1128–1130.
23. Rönnekaa T, Rönnekaa EM, Puukka P, Pyörälä K, Laakso M. Smoking is independently associated with high plasma insulin levels in non diabetic men. *Diabetes Care*. 1996;19:1229–1232.
24. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*. 1997;82:3619–3624.
25. Attvall S, Fowelin J, Lager I, Von Schenck H, Smith U. Smoking induces insulin resistance: a potential link with the insulin resistance syndrome. *J Intern Med*. 1993;233:327–332.
26. Wada T, Urashima M, Fukumoto T. Risk of metabolic syndrome persists twenty years after the cessation of smoking. *Intern Med*. 2007;46:1079–1082.
27. Razay G, Heaton KW. Smoking habits and lipoproteins in British women. *Quart J Med*. 1995;88:503–508.
28. Lee WY, Jung CH, Park JS, Rhee EJ, Kim SW. Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III. *Diabetes Res Clin Pract*. 2005;67:70–77.
29. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. *Angiology*. 2003;54:507–530.
30. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. *Circulation*. 1987;75:124–130.
31. Criqui MH, Wallace RB, Heiss G, Mishkel M, Schonfeld G, Jones GT. Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. *Circulation*. 1980;62:IV70–IV76.
32. Nakanishi N, Takatorige T, Suzuki K. Cigarette smoking and the risk of the metabolic syndrome in middle-aged Japanese male office workers. *Ind Health*. 2005;43:295–301.
33. Miyatake N, Wada J, Kawasaki Y, Nishii K, Makino H, Numata T. Relationship between metabolic syndrome and cigarette smoking in the Japanese population. *Intern Med*. 2006;45:1039–1043.
34. Geslain-Biquez C, Vol S, Tichet J, Caradec A, D'Hour A, Balkau B. The metabolic syndrome in smokers. The D.E.S.I.R. study. *Diabetes Metab*. 2003;29:226–234.
35. Saarni SE, Pietiläinen K, Kantonen S, Rissanen A, Kaprio J. Association of smoking in adolescence with abdominal obesity in adulthood: a follow-up study of 5 birth cohorts of Finnish twins. *Am J Public Health*. 2009;99:348–354.
36. Kawada T, Otsuka T, Inagaki H, et al. Association of smoking status, insulin resistance, body mass index, and metabolic syndrome in workers: a 1-year follow-up study. *Obes Res Clin Pract*. 2010;4:e163–e169.
37. Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? *J Am Coll Cardiol*. 2003;41:1044–1047.
38. Beaser RS, Levy P. Metabolic syndrome: a work in progress, but a useful construct. *Circulation*. 2007;115:1812–1818.
39. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. *Diabetes*. 2005;54:1899–1906.
40. Maier S, Olek A. Diabetes: a candidate disease for efficient DNA methylation profiling. *J Nutr*. 2002;132(Suppl 8):S2440–S2443.
41. Wren JD, Garner HR. Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes. *J Biomed Biotechnol*. 2005;2005:104–112.
42. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum

- from current and former smokers. *Cancer Res.* 2002;62:2370–2377.
43. Ross CM. Letter regarding article by Weitzman et al. "Tobacco smoke exposure is associated with the metabolic syndrome in adolescents." *Circulation.* 2006;113:e393. Author reply e393.
 44. Eliasson B, Attvall S, Taskinen MR, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. *Arterioscler Thromb.* 1994;14:1946–1950.
 45. Ronnema T, Ronnema EM, Puukka P, Pyorala K, Laakso M. Smoking is independently associated with high plasma insulin levels in nondiabetic men. *Diabetes Care.* 1996;19:1229–1232.
 46. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. *Circulation.* 1996;94:878–881.
 47. Eliasson B, Attvall S, Taskinen MR, Smith U. Smoking cessation improves insulin sensitivity in healthy middle-aged men. *Eur J Clin Invest.* 1997;27:450–456.
 48. Eliasson B. Cigarette smoking and diabetes. *Prog Cardiovasc Dis.* 2003;45:405–413.
 49. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA.* 2007;298:2654–2664.
 50. Manson JE, Ajani UA, Liu S, Nathan DM, Hennekens CH. A prospective study of cigarette smoking and the incidence of diabetes mellitus among U.S. male physicians. *Am J Med.* 2000;109:538–542.
 51. Rimm EB, Manson JE, Stampfer MJ, et al. Cigarette smoking and the risk of diabetes in women. *Am J Public Health.* 1993;83:211–214.
 52. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med.* 2001;345:790–797.
 53. Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. *Int J Epidemiol.* 2001;30:540–546.
 54. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. *BMJ.* 1995;310:555–559.
 55. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab.* 1997;82:3619–3624.
 56. Koska J, Stefan N, Permana PA, et al. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals. *Am J Clin Nutr.* 2008;87:295–302.
 57. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. *Mol Cell Endocrinol.* 2010;314:1–16.
 58. Friedman J. Fat in all the wrong places. *Nature.* 2002;415:268–269.
 59. Mizuno O, Okamoto K, Sawada M, Mimura M, Watanabe T, Morishita T. Obesity and smoking: relationship with waist circumference and obesity-related disorders in men undergoing a health screening. *J Atheroscler Thromb.* 2005;12:199–204.
 60. Han TS, Sattar N, Lean M. ABC of obesity. Assessment of obesity and its clinical implications. *BMJ.* 2006;333:695–698.
 61. Pasquali R, Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. *Int J Obes Relat Metab Disord.* 2000;24(Suppl):S47–S49.
 62. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. *N Engl J Med.* 1976;295:573–577.
 63. Friedman AJ, Ravnkar VA, Barbieri RL. Serum steroid hormone profiles in postmenopausal smokers and non-smokers. *Fertil Steril.* 1987;47:398–401.
 64. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. *N Engl J Med.* 1991;324:739–745.
 65. Yoshida T, Sakane N, Umekawa T, et al. Nicotine induces uncoupling protein 1 in white adipose tissue of obese mice. *Int J Obes Relat Metab Disord.* 1999;23:570–575.
 66. Haarlo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. *Metabolism.* 1991;40:1323–1326.
 67. Bjorntorp P. Abdominal obesity and the development of noninsulin-dependent diabetes mellitus. *Diabetes Metab Rev.* 1988;4:615–622.
 68. Evans DJ, Barth JH, Burke CW. Body fat topography in women with androgen excess. *Int J Obes.* 1988;12:157–162.
 69. Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. *J Clin Endocrinol Metab.* 1997;82:2044–2047.
 70. Khaw KT, Tazuke S, Barrett-Connor E. Cigarette smoking and levels of adrenal androgens in postmenopausal women. *N Engl J Med.* 1988;318:1705–1709.
 71. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. *N Engl J Med.* 1986;315:1305–1309.
 72. Dai WS, Gutai JP, Kuller LH, Cauley JA. Cigarette smoking and serum sex hormones in men. *Am J Epidemiol.* 1988;128:796–805.
 73. Barrett-Connor E, Khaw KT. Cigarette smoking and increased endogenous estrogen levels in men. *Am J Epidemiol.* 1987;126:187–192.
 74. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. *J Endocrinol Invest.* 1999;22:110–116.
 75. Marin P. Testosterone and regional fat distribution. *Obes Res.* 1995;3(Suppl):S609–S612.
 76. Meikle AW, Liu XH, Taylor GN, Stringham JD. Nicotine and cotinine effects on 3 alpha hydroxysteroid dehydrogenase in canine prostate. *Life Sci.* 1988;43:1845–1850.
 77. Eliasson B, Smith U. Leptin levels in smokers and long-term users of nicotine gum. *Eur J Clin Invest.* 1999;29:145–152.
 78. Kennedy A, Gettys TW, Watson P, et al. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. *J Clin Endocrinol Metab.* 1997;82:1293–1300.
 79. Saad MF, Damani S, Gingerich RL, et al. Sexual dimorphism in plasma leptin concentration. *J Clin Endocrinol Metab.* 1997;82:579–584.
 80. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med.* 1996;334:292–295.
 81. Taylor SI, Barr V, Reitman M. Does leptin contribute to diabetes caused by obesity? *Science.* 1996;274:1151–1152.

82. Nicklas BJ, Tomoyasu N, Muir J, Goldberg AP. Effects of cigarette smoking and its cessation on body weight and plasma leptin levels. *Metabolism*. 1999;48:804–808.
83. Perkins KA, Fonte C. Effects of smoking status and smoking cessation on leptin levels. *Nicotine Tob Res*. 2002;4:459–466.
84. Martin LJ, Kissebah AH, Sonnenberg GE, Blangero J, Comuzzie AG. Metabolic Risk Complications of Obesity Genes Project. Genotype-by-smoking interaction for leptin levels in the Metabolic Risk Complications of Obesity Genes project. *Int J Obes Relat Metab Disord*. 2003;27:334–340.
85. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. *Obes Rev*. 2004;5:95–103.
86. Hodge AM, Westerman RA, de Courten MP, Collier GR, Zimmet PZ, Alberti KG. Is leptin sensitivity the link between smoking cessation and weight gain? *Int J Obes Relat Metab Disord*. 1997;21:50–53.
87. Wei M, Stern MP, Haffner SM. Serum leptin levels in Mexican Americans and non-Hispanic whites: association with body mass index and cigarette smoking. *Ann Epidemiol*. 1997;7:81–86.
88. Larsson H, Ahren B. Smoking habits and circulating leptin in postmenopausal non-obese women. *Diabetes Obes Metab*. 1999;1:57–59.
89. Donahue RP, Zimmet P, Bean JA, et al. Cigarette smoking, alcohol use, and physical activity in relation to serum leptin levels in a multiethnic population: the Miami Community Health Study. *Ann Epidemiol*. 1999;9:108–113.
90. Lee H, Joe KH, Kim W, et al. Increased leptin and decreased ghrelin level after smoking cessation. *Neurosci Lett*. 2006;409:47–51.
91. Chagnon YC, Wilmore JH, Borecki IB, et al. Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. *J Clin Endocrinol Metab*. 2000;85:29–34.
92. Mattevi VS, Zembruski VM, Hutz MH. Association analysis of genes involved in the leptin-signaling pathway with obesity in Brazil. *Int J Obes Relat Metab Disord*. 2002;26:1179–1185.
93. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI. A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. *Hum Genet*. 2001;108:233–236.
94. Van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC. Genetic variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults. *Obes Res*. 2003;11:377–386.
95. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. *Ann Intern Med*. 1999;130:671–680.
96. Bishop C, Parker GC, Coscina DV. Nicotine and its withdrawal alter feeding induced by paraventricular hypothalamic injections of neuropeptide Y in Sprague-Dawley rats. *Psychopharmacology*. 2002;162:265–272.
97. Li MD, Parker SL, Kane JK. Regulation of feeding-associated peptides and receptors by nicotine. *Mol Neurobiol*. 2000;22:143–165.
98. Chen H, Hansen MJ, Jones JE, et al. Regulation of hypothalamic NPY by diet and smoking. *Peptides*. 2007;28:384–389.
99. Chen H, Vlahos R, Bozinovski S, Jones J, Anderson GP, Morris MJ. Effect of short-term cigarette smoke exposure on body weight, appetite and brain neuropeptide Y in mice. *Neuropsychopharmacology*. 2005;30:713–719.
100. Jo YH, Talmage DA, Role LW. Nicotinic receptor-mediated effects on appetite and food intake. *J Neurobiol*. 2002;53:618–632.
101. Bourros D, Tzouveleakis A, Anevlavis S, et al. Smoking acutely increases plasma ghrelin concentrations. *Clin Chem*. 2006;52:777–778.
102. Klesges RC, Winders SE, Meyers AW, et al. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. *J Consult Clin Psychol*. 1997;65:286–291.
103. Flegal KM, Troiano RP, Pamuk ER, Kuczmarski RJ, Campbell SM. The influence of smoking cessation on the prevalence of overweight in the United States. *N Engl J Med*. 1995;333:1165–1170.
104. Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P. Interventions for preventing weight gain after smoking cessation. *Cochrane Database Syst Rev*. 2009;(1):CD006219.
105. LaRowe TL, Piper ME, Schlam TR, Fiore MC, Baker TB. Obesity and smoking: comparing cessation treatment seekers with the general smoking population. *Obesity*. 2009;17:1301–1305.
106. Albanes D, Jones DY, Micozzi MS, Mattson ME. Associations between smoking and body weight in the U.S. population: analysis of NHANES II. *Am J Public Health*. 1987;77:439–444.
107. Ward KD, Klesges RC, Vander Weg MW. Cessation of smoking and body weight. In: Björntop P, ed. *International Textbook of Obesity*. Chichester, UK: Wiley & Sons Ltd; 2001:323–336.
108. Kruger J, Ham SA, Prohaska TR. Behavioral risk factors associated with overweight and obesity among older adults: the 2005 National Health Interview Survey. *Prev Chronic Dis*. 2009;6:A14.
109. Kim BJ, Kim BS, Sung KC, Kang JH, Lee MH, Park JR. Association of smoking status, weight change, and incident metabolic syndrome in men: a 3-year follow-up study. *Diabetes Care*. 2009;32:1314–1316.
110. Bradley DP, Johnson LA, Zhang Z, et al. Effect of smoking status on total energy expenditure. *Nutr Metab*. 2010;7(81):1–6.
111. Chioloro A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. *Am J Clin Nutr*. 2008;87:801–809.
112. Dallosso HM, James WP. The role of smoking in the regulation of energy balance. *Int J Obes*. 1984;8:365–375.
113. Hofstetter A, Schutz Y, Jequier E, Wahren J. Increased 24-hour energy expenditure in cigarette smokers. *N Engl J Med*. 1986;314:79–82.
114. Walker J, Collins LC, Nannini L, Stamford BA. Potentiating effects of cigarette smoking and moderate exercise on the thermic effect of a meal. *Int J Obes Relat Metab Disord*. 1992;16:341–347.
115. Stamford BA, Matter S, Fell RD, Papanek P. Effects of smoking cessation on weight gain, metabolic rate, caloric consumption, and blood lipids. *Am J Clin Nutr*. 1986;43:486–494.
116. Burse RL, Bynum GD, Pandolf KB, Goldman RF, Sims EAH, Danforth E. Increased appetite and unchanged metabolism upon cessation of smoking with diet held constant. *Physiologist*. 1975;18:157.
117. Moffatt RJ, Owens SG. Cessation from cigarette smoking: changes in body weight, body composition, resting metabolism, and energy consumption. *Metabolism*. 1991;40:465–470.

118. Koster A, Leitzmann MF, Schatzkin A, et al. The combined relations of adiposity and smoking on mortality. *Am J Clin Nutr*. 2008;88:1206–1212.
119. Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. *Am J Public Health*. 2002;92:990–996.
120. Pisinger C, Jorgensen T. Waist circumference and weight following smoking cessation in a general population: the Inter99 study. *Prev Med*. 2007;44:290–295.
121. Chiang PH, Chang TY, Chen JD. Synergistic effect of fatty liver and smoking on metabolic syndrome. *World J Gastroenterol*. 2009;15:5334–5339.
122. World Health Organization. *World Health Report 2002: Reducing Risks, Promoting Healthy Life*. Geneva, Switzerland: WHO; 2002. Available at: http://www.who.int/whr/2002/en/why02_en.pdf. Accessed 31 October 2011.
123. World Health Organization. In: Branca F, Nikogosian H, Lobstein T, eds. *The Challenge of Obesity in the WHO European Region and the Strategies for Response*. Copenhagen, Denmark: WHO; 2007. Available at: http://www.euro.who.int/_data/assets/pdf_file/0008/98243/E89858.pdf. Accessed 31 October 2011.